Ardelyx, Inc. Q2 2026 Earnings Recap

Ardelyx shares fell 18.5% after the company cut guidance in response to growing payer hurdles that slowed new patient starts for IBSRELA, signaling investor concerns over demand deceleration despite revenue growth.

Key Takeaways

• Combined revenue from IBSRELA and XPHOZAH reached $118 million, up 31% year-over-year and the highest quarterly total in company history.
• New patient starts for IBSRELA were materially impacted by increased payer restrictions, dampening growth momentum.
• Refill rates and total prescriptions hit record highs, supported by the IBSRELA Pharmacy Network and expanded sales force initiatives.
• The company highlighted ongoing efforts to mitigate payer barriers, including doubling the field reimbursement team and ramping up direct-to-consumer marketing.
• Management reaffirmed long-term revenue potential but will no longer pursue further legal action regarding CMS reimbursement, removing a potential lever for future pricing flexibility.